Inclusion Criteria:

- Subjects having histologically and/or cytologically confirmed non-haematological
malignancy that is metastatic or unresectable and for which standard curative or
palliative treatment does not exist or is no longer effective

- Subjects should have measurable or evaluable disease

- Subjects of either sex, of all races and ethnic groups, and ≥18 years of age

- ECOG (Eastern Cooperative Oncology Group) performance status 0-1

- Subjects with life expectancy of at least 4 months

- Subjects with fasting plasma glucose ≤ 125 mg/dL and HbA1c < 6.5 % at screening
Subjects with fasting plasma glucose ≤150 mg/dL and HbA1c ≤ 7.0 % at screening for
the Diabetes Expansion Cohort.

- For the Diabetes Expansion Cohort - Subjects with known history of type 2 diabetes
mellitus that are well-controlled on a stable dose of oral anti-diabetic agents such
as metformin and/or sulfonylureas for 4 weeks prior to screening.

- Subjects must have normal organ and marrow function as defined below:

1. Absolute neutrophil count ≥ 1500/cmm

2. Platelets ≥ 100,000/cmm

3. Total bilirubinwithin normal limits of the institution

4. AST/ALT ≤ 2.5 X institutional upper limit of normal (ULN) or ≤ 5 X institutional
upper limit of normal (ULN) in the presence of liver metastases

5. Creatinine ≤ 1.5 X institutional upper limit of normal (ULN)

- Subjects willing for repeat oral dosing and follow-up, including pharmacokinetic
sampling

- Women of childbearing potential and men willing to agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to
study entry, during the duration of study participation and for at least 4 weeks
after withdrawal from the study, unless they are surgically sterilised

- Ability to understand and the willingness to provide a written informed consent
document

Exclusion Criteria

- Subjects who have received any prior chemotherapy, radiotherapy, biologic/targeted
anti-cancer therapy or surgery within 4 weeks (6 weeks for monoclonal antibodies,
radioactive monoclonal antibodies or any radio- or toxin- immunoconjugates) before
the first study drug administration and have not recovered (to AEs < Grade 2) from
the toxic effects from any prior therapy

- Subjects having received any other investigational agents within 4 weeks prior to the
first study drug administration and have not recovered completely (to AEs < Grade 2)
from the side effects of the earlier investigational agent

- Subjects with documented history of diabetes mellitus except for the Diabetes
Expansion Cohort

- For the Diabetes Expansion Cohort - Subjects who have type 1 diabetes mellitus,
maturity onset diabetes of the young, hyperglycemia due to reasons other than type 2
diabetes mellitus.

- For the Diabetes Expansion Cohort - Subjects who currently require insulin,
thiazolidinediones, dual proliferator-activated receptors (PPAR) agonists,
glucagon-like peptide (GLP-1) analogues, dipeptidyl peptidase (DPP-IV) inhibitors or
have received the same in the 4 weeks prior to screening.

- Subjects with known complications of diabetes like diabetic nephropathy or diabetic
retinopathy

- Subjects with known brain metastases

- Subjects with gastrointestinal abnormalities including inability to take oral
medication, malabsorption or other conditions like chronic inflammatory bowel disease
that may affect absorption.

- Subjects with a history of myocardial infarction or uncontrolled cardiac dysfunction
during the previous 6 months

- Subjects with baseline QTc interval >470 msec at screening

- Subjects on warfarin. Prophylactic anticoagulation with low molecular weight heparin
is allowed

- Subjects with history of anaphylaxis or angioedema, bronchial asthma, peptic ulcer
and clinically significant food or drug allergy

- Subjects with uncontrolled intercurrent illness including, but not limited to ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements

- Women who are pregnant or nursing

- Subjects with known seropositivity to human immunodeficiency virus (HIV), positive
for Hepatitis B, positive for Hepatitis C (antigen positive), or known hepatic
cirrhosis